Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Told you this was junk status

<< Previous

Bullboard Posts

Next >>

Comment by Bubbsy2014on Jan 13, 2021 2:50pm

209 Views

Post# 32286750

RE:Told you this was junk status

Ya. Open up a Vdick post and then hit his name. It shows the constant bullsh$t. He spews. Knows nothing. The stock just recovered since his post 3 hours ago. I’m holding. I agree about Weed. It went from $3 to $17. Then tanked. Smart investors didn’t sell. Bubbs.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments